The European Commission awarded Glycanostics the prestigious Seal of Excellence for its revolutionary prostate cancer early diagnostic tests. This project was submitted under the Horizon 2020 Programme for Research and Innovation 2014-2020, and received the highest scores for its proposal in the extremely competitive evaluation process. The European Commission has a rigorous evaluation system—with a panel of international, independent experts—based on three criteria: excellence, impact and quality, and efficiency of implementation.
Jan Tkac, Сo-Founder and Executive Manager of Glycanostics Ltd., comments:
“It feels really great to be ranked among the best projects by the leading EU industry experts! And again, it's another confirmation that our products are innovative, meet market needs, and have an efficient business model!”
The Glycanostics’ team plans to continue with new H2020 submissions. Now, with the Seal of Excellence, the company's chances are significantly higher! This award also increases the investment appeal of the company as the Seal is a label of quality which identifies promising projects and recommends them for funding from alternative sources, be they public or private, regional or national, European or international.
Horizon 2020 is the biggest EU Research and Innovation Programme ever. The program identifies and supports breakthroughs, discoveries, and world-firsts by taking great ideas from the lab to the market. The Seal of Excellence is a “high-quality” label awarded to those projects submitted to Horizon 2020 which were deemed deserving of funding, but did not receive it due to budget limitations. The Seal of Excellence Certificate rewards the best unfunded proposals with the ability to approach alternative regional, national, private, or public funding sources. In addition, it helps funding bodies wanting to invest in the most promising proposals (including national & regional authorities through European Structural & Investment Funds) to identify these projects more easily.
Glycanostics was chosen as a finalist in the Grand Finale with five other remarkable startups.
Glycanoctics innovations are again supported and highly ranked by leading industry experts. This time the company won the European Research Council (ERC) Proof of Concept Grant.
In April 2018 the technology validation was successfully completed indicating a great potential of Glycanostics innovative products for prostate cancer (PCa) diagnostics.
Glycanostics is an innovative start-up company established in 2017 to bring its revolutionary cancer diagnostics products to the US and EU markets.